Basic and patient-oriented researchSerologic Bone Markers for Predicting Development of Osteonecrosis of the Jaw in Patients Receiving Bisphosphonates
Section snippets
Patients
The study population included patients receiving oral or intravenous BP treatment who were referred to the Department of Oral and Maxillofacial Surgery, Sheba Medical Center (Tel Hashomer, Israel) for dentoalveolar surgery from 2007 to 2008. Patients receiving intravenous BPs underwent dentoalveolar surgery only when it was unavoidable. The criteria for study exclusion were a previous diagnosis of BRONJ in the same quadrant of the jaw in which the index surgical procedure was scheduled, a
Patients
A total of 78 consenting patients fulfilled the selection criteria and were included in the present study. Table 1 lists the patient characteristics (gender, age, indication for BP, BP type, and comorbidities).
Bisphosphonate Consumption
Of the 78 patients, 44 (56.4%) had received oral alendronate (70 mg once weekly or 10 mg once daily), 3 (3.9%) had received oral risedronate (35 mg once weekly), and 4 (5.1%) had received the 2 drugs consecutively. The remaining 27 patients had received intravenous BPs: 10 (12.8%),
Discussion
The morbidity of BRONJ, its high incidence among patients receiving frequent intravenous infusions of BPs, and the large number of patients using oral BPs has spurred a vigorous search for predictive and prognostic factors for the development of BRONJ.30, 31 Biochemical markers of bone resorption and bone formation can be used to assess the level of bone turnover.18, 19, 20, 21 Collagen I is an abundant constituent of bone, reaching up to 90% of the organic matrix, and is synthesized primarily
Acknowledgment
The authors thank Prof Amos Buchner for his valuable contribution to the preparation of the manuscript and Mrs Esther Eshkol for editorial assistance.
References (45)
- et al.
Osteonecrosis of the jaws associated with cancer chemotherapy
J Oral Maxillofac Surg
(2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
J Oral Maxillofac Surg
(2003)- et al.
Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases
J Oral Maxillofac Surg
(2004) - et al.
Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: Risk factors, recognition, prevention, and treatment
J Oral Maxillofac Surg
(2005) - et al.
Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper
J Am Dent Assoc
(2005) - et al.
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia
J Oral Maxillofac Surg
(2007) - et al.
Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients
J Oral Maxillofac Surg
(2009) - et al.
Bisphosphonate-related osteonecrosis of the jaws associated with dental implants
J Oral Maxillofac Surg
(2010) - et al.
Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?
J Oral Maxillofac Surg
(2005) - et al.
Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women
Bone
(2000)
How long should patients take medications for postmenopausal osteoporosis?
Joint Bone Spine
Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk
Clin Ther
Bis-phossy jaws—High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw
J Craniomaxillofac Surg
Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment
J Oral Maxillofac Surg
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws
J Oral Maxillofac Surg
Bone turnover markers in Spanish postmenopausal women: The Camargo cohort study
Clin Chim Acta
Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment
J Oral Maxillofac Surg
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates
Oral Oncol
Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws
J Oral Maxillofac Surg
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
Ann Oncol
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure: Predicting risk of osteonecrosis of the jaw with oral bisphosphonate Exposure (PROBE) Investigators
J Oral Maxillofac Surg
Cited by (91)
Oral and maxillofacial literature from Middle East: a bibliometric analysis and list of top-100 most cited articles
2023, Journal of Stomatology, Oral and Maxillofacial SurgeryUtility of biomarkers in predicting the development of medication-related osteonecrosis of the jaws: A scoping review
2023, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyRisk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients
2022, Brazilian Journal of OtorhinolaryngologyBiochemical markers of bone turnover in osteoporosis
2020, Marcus and Feldman’s OsteoporosisSerum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis
2019, Journal of the American Dental AssociationCitation Excerpt :The search involved data from 2,301 patients enrolled in the 18 clinical trials.25,30-46 The mean age across the 18 trials25,30-46 was 67.6 years. Most of the recruited patients were receiving BPs for the treatment of osteoporosis or to reduce skeletal-related events, such as pathologic fractures, metastasis, or hypercalcemia, associated with malignancy (eTable 1).25,30-46
Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case–control study
2019, Journal of Cranio-Maxillofacial Surgery